Pre-made Tesidolumab benchmark antibody ( Whole mAb, anti-C5/CO5 therapeutic antibody, Anti-CPAMD4/ECLZB Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tesidolumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tesidolumab, as known as LFG-316, is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the complement pathway protein C5, with complement pathway inhibitory activity and potential immunomodulating activity.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-565-1mg	1mg	3090
GMP-Bios-ab-565-10mg	10mg	Inquiry
GMP-Bios-ab-565-100mg	100mg	Inquiry
GMP-Bios-ab-565-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tesidolumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody
INN Name	Tesidolumab
Target	CO5
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	MorphoSys;Novartis
Conditions Approved	na
Conditions Active	Paroxysmal nocturnal haemoglobinuria
Conditions Discontinued	Choroiditis;Dry age-related macular degeneration;Panuveitis;Thrombotic microangiopathy;Wet age-related macular degeneration
Development Tech	MorphoSys HuCAL Phage Display;XmAb Engineering Technology